Rna-Coded Antibody - EP3115064

The patent EP3115064 was granted to Curevac on Nov 24, 2021. The application was originally filed on Jan 8, 2008 under application number EP16001146A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3115064

CUREVAC
Application Number
EP16001146A
Filing Date
Jan 8, 2008
Status
Granted And Under Opposition
Oct 22, 2021
Grant Date
Nov 24, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MODERNAAug 24, 2022EIPADMISSIBLE

Patent Citations (35) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP1083232
DESCRIPTIONUS4373071
DESCRIPTIONUS4401796
DESCRIPTIONUS4415732
DESCRIPTIONUS4458066
DESCRIPTIONUS4500707
DESCRIPTIONUS4668777
DESCRIPTIONUS4973679
DESCRIPTIONUS5047524
DESCRIPTIONUS5132418
DESCRIPTIONUS5153319
DESCRIPTIONUS5262530
DESCRIPTIONUS5700642
DESCRIPTIONWO02098443
EXAMINATIONUS2004142885
EXAMINATIONUS2005221435
EXAMINATIONWO2008052770
EXAMINATIONWO9011092
OPPOSITIONEP1083232
OPPOSITIONEP1084246
OPPOSITIONUS2004132683
OPPOSITIONUS2004142885
OPPOSITIONUS2005221435
OPPOSITIONUS5580859
OPPOSITIONUS6214804
OPPOSITIONWO2006024518
OPPOSITIONWO2008052770
OPPOSITIONWO2017186928
OPPOSITIONWO9011092
OPPOSITIONWO9914346
OTHERWO2017186928
SEARCHUS2003153735
SEARCHUS5736137
SEARCHWO2004085474
SEARCHWO2007024708

Non-Patent Literature (NPL) Citations (103) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AKASHI, CURR. OPIN. GENET. DEV., (2001), vol. 11, no. 6, pages 660 - 666-
DESCRIPTION- ALTSCHUL ET AL., NUCLEIC ACIDS RES, (1997), vol. 25, pages 3389 - 3402-
DESCRIPTION- BAKKE ET AL., CELL, (1990), vol. 63, pages 707 - 716-
DESCRIPTION- BEYERSDORF N; HANKE T; KERKAU T; HUNIG T, "Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases", ANN RHEUM DIS., (200511), page 64-
DESCRIPTION- BINDER ET AL., EMBO J., (1994), vol. 13, pages 1969 - 1980-
DESCRIPTION- CAPUT ET AL., PROC. NATL. ACAD. SCI. USA, (1986), vol. 83, pages 1670 - 1674-
DESCRIPTION- CROOKE ET AL., J. PHARMACOL. EXP. THER., (1996), vol. 277, page 923-
DESCRIPTION- GILKESON ET AL., J. CLIN. INVEST., (1995), vol. 95, pages 1398 - 1402-
DESCRIPTION- GROSSE-HOVEST L. ET AL., EUR. IMMUNOL., (2003), vol. 33, no. 5, pages 1334 - 40-
DESCRIPTION- HANGEJORDEN ET AL., J. BIOL. CHEM., (1991), vol. 266, page 6015-
DESCRIPTION- HAR-LOW ET AL., MOL. CELL BIOL., (1985), vol. 5, page 1605-
DESCRIPTION- HOLCIK ET AL., PROC. NATL. ACAD. SCI. USA, (1997), vol. 94, pages 2410 - 2414-
DESCRIPTION- KABANOV ET AL., FEBS LETT., (1990), vol. 259, page 327-
DESCRIPTION- KARLIN ET AL., PNAS USA, (1993), vol. 90, pages 5873 - 5877-
DESCRIPTION- KONTERMANN R.E., ACTA PHARMACOL. SIN, (2005), vol. 26, no. 1, pages 1 - 9-
DESCRIPTION- KUBOTA ET AL., BIOCHEM. AND BIOPHY, RES. COMM., (1989), vol. 162, page 963-
DESCRIPTION- LAI ET AL., DEVELOPMENT, (1995), vol. 121, pages 2349 - 2360-
DESCRIPTION- LANFORD ET AL., CELL, (1986), vol. 46, page 575-
DESCRIPTION- LETOUMEUR ET AL., CELL, (1992), vol. 69, page 1183-
DESCRIPTION- MANOHARAN ET AL., NUCLEOSIDES & NUCLEOTIDES, (1995), vol. 14, page 969-
DESCRIPTION- MANOHARAN ET AL., TETRAHEDRON LETT., (1995), vol. 36, page 3651-
DESCRIPTION- MISHRA ET AL., BIOCHIM. BIOPHYS. ACTA, (1995), vol. 1264, page 229-
DESCRIPTION- MONTHEITH ET AL., ANTICANCER DRUG RES., (1997), vol. 12, no. 5, pages 421 - 432-
DESCRIPTION- MUNRO ET AL., CELL, (1987), vol. 48, pages 899 - 907-
DESCRIPTION- OBERHAUSER ET AL., NUCL. ACIDS RES., (1992), vol. 20, page 533-
DESCRIPTION- P. A. KRIEG; D. A. MELTON, "In vitro RNA synthesis with SP6 RNA polymerase", METHODS ENZYMOL, (1987), vol. 155, pages 397 - 415-
DESCRIPTION- SAISON-BEHMOARAS ET AL., EMBO J, (1991), vol. 10, page 111-
DESCRIPTION- SEOMI ET AL., J. VIROLOGY, (1990), vol. 64, page 1803-
DESCRIPTION- SHEA ET AL., NUCL. ACIDS RES., (1990), vol. 18, page 3777-
DESCRIPTION- SIOMI ET AL., CELL, (1988), vol. 55, page 197-
DESCRIPTION- STANTON, L. W. ET AL., PROC. NATL. ACAD. SCI USA, (1986), vol. 83, page 1772-
DESCRIPTION- STINCHCOMB ET AL., NATURE, (1997), vol. 282, page 39-
DESCRIPTION- SVINARCHUK ET AL., BIOCHIMIE, (1993), vol. 75, page 49-
DESCRIPTION- TANG ET AL., J. BIO. CHEM., vol. 207, page 10122-
DESCRIPTION- MARASCO WA, "intrabodies: turning the humoral immune system outside in for intracellular immunization", GENE THERAPY, (1997), vol. 4, doi:doi:10.1038/sj.gt.3300346, pages 11 - 15, XP002097642
DESCRIPTION- SMITH, G.P., "Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface", SCIENCE, (1985), vol. 228, doi:doi:10.1126/science.4001944, pages 1315 - 1317, XP002464311
EXAMINATION- KURT-JONES E A ET AL, "The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 01 JUN 1988, (19880601), vol. 140, no. 11, ISSN 0022-1767, pages 3773 - 3778-
EXAMINATION- LEEF M ET AL, "Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production.", THE JOURNAL OF EXPERIMENTAL MEDICINE 05 JUN 2000, (20000605), vol. 191, no. 11, ISSN 0022-1007, pages 1841 - 1852-
EXAMINATION- NATURE 28 MAY 1981, (19810528), vol. 291, no. 5813, ISSN 0028-0836, pages 338 - 340-
EXAMINATION- VALLE G ET AL, "Synthesis and secretion of mouse immunoglobulin chains from Xenopus oocytes.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (19810528), Database accession no. NLM6785656-
EXAMINATION- VALLE G ET AL, "Synthesis and secretion of mouse immunoglobulin chains from Xenopus oocytes.", NATURE 28 MAY 1981, (19810528), vol. 291, no. 5813, ISSN 0028-0836, pages 338 - 340, XP002764726-
EXAMINATION- BETTINGER T ET AL, "Peptide-mediated RNA delivery: a novel approach for enhanced transfection of primary and post-mitotic cells.", NUCLEIC ACIDS RESEARCH 15 SEP 2001, (20010915), vol. 29, no. 18, doi:10.1093/nar/29.18.3882, ISSN 1362-4962, pages 3882 - 3891, XP002390292
OPPOSITION- Fernandez-Pol Jose A, "Epidermal Growth Factor Receptor of A431 Cells - CHARACTERIZATION OF A MONOCLONAL ANTI-RECEPTOR ANTIBODY NONCOMPETITIVE AGONIST OF EPIDERMAL GROWTH FACTOR ACTION", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (19850425), vol. 260, no. 8, pages 5003 - 5011, XP055964087-
OPPOSITION- HOERR INGMAR, "Stabilized messenger RNA (RNActive (TM)) as a tool for innovative gene delivery", TISSUE ENGINEERING, & 2ND INTERNATIONAL CONGRESS ON REGENERATIVE BIOLOGY/2ND INTERNATIONAL CONGRESS ON BIO-NANO-INTERFACE; STUTTGART, GERMANY; OCTOBER 09 -11, 2006, (20070401), vol. 13, no. 4, pages 886 - 887, XP009125215-
OPPOSITION- Kitaguchi Kohji; Toda Mikako; Takekoshi Masataka; Maeda Fumiko; Muramatsu Tatsuo; Murai Atsushi, "Immune deficiency enhances expression of recombinant human antibody in mice after nonviral in vivo gene transfer", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, GR , (20051001), vol. 16, no. 4, ISSN 1107-3756, pages 683 - 688, XP008118466-
OPPOSITION- KOLB et al., "Expression of a recombinant monoclonal antibody from a bicistronic mRNA", Hybridoma, (19970000), vol. 16, no. 5, pages 421 - 426, XP009006485-
OPPOSITION- Pascolo, Steve, "Chapter 27 - RNA-based therapies", Pascolo, Steve, Cox, Shayne, Drug Discovery Handbook, Wiley, (20050101), pages 1259 - 1308, XP055964124-
OPPOSITION- WANG et al., "Noninvasive monitoring of target gene expression by imaging reporter gene expression in living animals using improved bicistronic vectors", THE JOURNAL OF NUCLEAR MEDICINE, (20050000), vol. 46, no. 4, XP008130958-
OPPOSITION- Weiler R., Feichtinger H., Schmid K.W., Fischer-Colbrie R., Grimelius L., Cedermark B., Papotti M., Bussolati G., Winkler H., "Chromogranin A and B and secretogranin II in bronchial and intestinal carcinoids", Virchows Arch A, (19870101), vol. 412, pages 103 - 109, XP055964109-
OPPOSITION- HOERR I. et al., "In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies", European Journal of Immunology, Hoboken, USA, (20000101), vol. 30, no. 1, ISSN 0014-2980, pages 1 - 7, XP002243972
OPPOSITION- STEVE PASCOLO, "Plasmid DNA and messenger RNA for therapy", Handbook of Pharmaceutical Biotechnology, (20070000), doi:10.1002/9780470117118.ch07b, pages 971 - 1011, XP055626043
OPPOSITION- MIZUGUCHI et al., "IRES-Dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector", MOLECULAR THERAPY, (20000000), vol. 1, no. 4, doi:10.1006/mthe.2000.0050, XP002213078
OPPOSITION- CARRALOT et al., "Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines", Cell Mol. Life Sci., (20040000), vol. 61, no. 18, doi:10.1007/s00018-004-4255-0, pages 2418 - 2424, XP037066067
OPPOSITION- SCHLAKE, "mRNA as novel technology for passive immunotherapy", Cellular and Molecular Life Sciences, (20190000), vol. 76, no. 2, doi:10.1007/s00018-018-2935-4, pages 301 - 328, XP036679412
OPPOSITION- HESS et al., "Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen", Cancer Immunol Immunother, (20060000), vol. 55, no. 6, doi:10.1007/s00262-005-0064-z, pages 672 - 683, XP019333249
OPPOSITION- BHATTACHARYA-CHATTERJEE et al., "Counterpoint. Cancer vaccines: single epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine", Cancer Immunol. Immunother., (20000000), vol. 49, no. 3, doi:10.1007/s002620050612, pages 133 - 141, XP037120624
OPPOSITION- Burke, B.; Warren, G., "Microinjection of mRNA coding for an anti-golgi antibody inhibits intracellular transport of a viral membrane protein", Cell, Amsterdam NL , (19840401), vol. 36, no. 4, doi:10.1016/0092-8674(84)90034-5, ISSN 0092-8674, pages 847 - 856, XP027462338
OPPOSITION- WEIDE et al., "Plasmid DNA- and messenger RNA-based anti-cancer vaccination", Immunol Lett, (20080000), vol. 115, no. 1, doi:10.1016/j.imlet.2007.09.012, pages 33 - 42, XP022400684
OPPOSITION- Katalin Kariko, Michael Buckstein, Houping Ni, Drew Weissman, "Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA", Immunity, AMSTERDAM, NL , (20050801), vol. 23, no. 2, doi:10.1016/j.immuni.2005.06.008, ISSN 1074-7613, pages 165 - 175, XP055548954
OPPOSITION- SADIKOGLOU et al., "Comparative analysis of internal ribosomal entry sites as molecular tools for bicistronic expression", Journal of Biotechnology, (20140000), vol. 181, doi:10.1016/j.jbiotec.2014.03.033, pages 31 - 34, XP029021613
OPPOSITION- KOLB et al., "A virus-neutralising antibody is not cytotoxic in vitro", Mol. Immunol, (20060000), vol. 43, doi:10.1016/j.molimm.2005.04.008, pages 677 - 689, XP025037174
OPPOSITION- IVANOVSKA et al., "Immunization with a DNA chimeric molecule encoding a hemagglutinin peptide and a scFv CD 21-specific antibody fragment induces long lasting IgM and CTL responses to influenza virus", Vaccine, (20060000), vol. 24, no. 11, doi:10.1016/j.vaccine.2005.10.029, pages 1830 - 1837, XP028011227
OPPOSITION- KURIEN et al., "Western blotting", Methods, (20060000), vol. 38, no. 4, doi:10.1016/j.ymeth.2005.11.007, pages 283 - 93, XP024908575
OPPOSITION- BAKKER et al., "Therapeutic antibody gene transfer: An active approach to passive immunity", Mol Ther, (20040000), vol. 10, no. 3, doi:10.1016/j.ymthe.2004.06.865, pages 411 - 416, XP004660582
OPPOSITION- SCHLAKE, "mRNA: A novel avenue to antibody therapy?", Molecular Therapy, (20190000), vol. 27, no. 4, doi:10.1016/j.ymthe.2019.03.002, XP055831379
OPPOSITION- THESS et al., "Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals", Am Soc Gene Cell Ther, (20150000), vol. 23, no. 9, doi:10.1038/mt.2015.103, pages 1456 - 1464, XP055316910
OPPOSITION- SAHIN et al., "mRNA-based therapeutics - developing a new class of drugs", Nature Reviews Drug Discovery, (20140000), vol. 13, doi:10.1038/nrd4278, pages 759 - 780, XP055544673
OPPOSITION- ZEYTIN et al., "Construction and characterization of DNA vaccines encoding the single-chain variable fragment of the anti-idiotype antibody 1 a7 mimicking the tumor-associated antigen disialoganglioside GD2", Cancer Gene Therapy, (20000000), vol. 7, no. 11, doi:10.1038/sj.cgt.7700240, pages 1426 - 1436, XP037757263
OPPOSITION- Probst J; Weide B; Scheel B; Pichler B J; Hoerr I; Rammensee H-G; Pascolo S, "Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent", Gene Therapy, GB , (20070503), vol. 14, no. 15, doi:10.1038/sj.gt.3302964, ISSN 0969-7128, pages 1175 - 1180, XP037772702
OPPOSITION- LUTZKY et al., "Antibody-based vaccines for the treatment of melanoma", Seminars in Oncology, (20020000), vol. 29, no. 5, doi:10.1053/sonc.2002.35241, pages 462 - 470, XP055415562
OPPOSITION- HILLMEN et al., "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria", N Engl J Med, (20060000), vol. 355, no. 12, doi:10.1056/NEJMoa061648, pages 1233 - 43, XP002482088
OPPOSITION- ROSA et al., "An antibody against secretogranin I (Chromogranin B) packaged into secretory granules", J Cell Biol, (19890000), vol. 109, doi:10.1083/jcb.109.1.17, pages 17 - 34, XP055410637
OPPOSITION- Igarashi T., Kobayashi Y., Ogura M., Kinoshita T., Ohtsu T., Sasaki Y., Morishima Y., Murate T., Kasai M., Uike N., Taniwaki M., Kano Y., Ohnishi K., Matsuno Y., Nakamura S., Mori S., Ohashi Y., Tobinai K., "Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study", Annals of Oncology, NL , (20020601), vol. 13, no. 6, doi:10.1093/annonc/mdf155, ISSN 0923-7534, pages 928 - 943, XP055964093
OPPOSITION- Tobinai K., Igarashi T., Itoh K., Kobayashi Y., Taniwaki M., Ogura M., Kinoshita T., Hotta T., Aikawa K., Tsushita K., Hiraoka A., Matsuno Y., Nakamura S., Mori S., Ohashi Y., "Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma", Annals of Oncology, NL , (20040501), vol. 15, no. 5, doi:10.1093/annonc/mdh176, ISSN 0923-7534, pages 821 - 830, XP055964090
OPPOSITION- Steven C. L. Ho, Bardor Muriel, Li Bin, Lee Jia, Song Zhiwei, Tong Yen, Goh Lin-Tang, Yang Yuansheng, Hendershot Linda, "Comparison of Internal Ribosome Entry Site (IRES) and Furin-2A (F2A) for Monoclonal Antibody Expression Level and Quality in CHO Cells", PLoS ONE, vol. 8, no. 5, doi:10.1371/journal.pone.0063247, page e63247, XP055258368
OPPOSITION- Esther Y. C. Koh, Steven C. L. Ho, Mariati, Zhiwei Song, Xuezhi Bi, Muriel Bardor, Yuansheng Yang, "An Internal Ribosome Entry Site (IRES) Mutant Library for Tuning Expression Level of Multiple Genes in Mammalian Cells", PLoS ONE, vol. 8, no. 12, doi:10.1371/journal.pone.0082100, page e82100, XP055328042
OPPOSITION- YOUN et al., "Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy", Expert Opin Biol Ther, (20150000), vol. 15, no. 9, doi:10.1517/14712598.2015.1057563, pages 1337 - 1348, XP055406240
OPPOSITION- Preissner Klaus T., Fischer Silvia, Deindl Elisabeth, "Extracellular RNA as a Versatile DAMP and Alarm Signal That Influences Leukocyte Recruitment in Inflammation and Infection", Frontiers in Cell and Developmental Biology, vol. 8, doi:10.3389/fcell.2020.619221, XP055964098
OPPOSITION- Gómez-Aguado Itziar, Rodríguez-Castejón Julen, Vicente-Pascual Mónica, Rodríguez-Gascón Alicia, Solinís María Ángeles, Del Pozo-Rodríguez Ana, "Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives", Nanomaterials, vol. 10, no. 2, doi:10.3390/nano10020364, page 364, XP055911347
OPPOSITION- SCHLAKE et al., "Developing mRNA-vaccine technologies", RNA Biology, (20120000), vol. 9, no. 11, doi:10.4161/rna.22269, pages 1319 - 1330, XP055561756
SEARCH- CREE BRUCE ET AL, "Tolerability and effects of Rituximab (anti-CD20 antibody) in neuromyelitis optica (NMO) and rapidly worsening multiple sclerosis (MS)", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, (20040401), vol. 62, no. 7, Suppl. 5, ISSN 0028-3878, page A492, XP009080814 [Y] 6 * the whole document *-
SEARCH- HOERR INGMAR, "Stabilized messenger RNA (RNActive (TM)) as a tool for innovative gene delivery", TISSUE ENGINEERING, & 2ND INTERNATIONAL CONGRESS ON REGENERATIVE BIOLOGY/2ND INTERNATIONAL CONGRESS ON BIO-NANO-INTERFACE; STUTTGART, GERMANY; OCTOBER 09 -11, 2006, (20070401), vol. 13, no. 4, pages 886 - 887, XP009125215 [PY] 24-26 * the whole document *-
SEARCH- KHARE P D ET AL, "TUMOR GROWTH SUPPRESSION BY A RETROVIRAL VECTOR DISPLAYING SCFV ANTIBODY TO CEA AND CARRYING THE INOS GENE", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, (20020101), vol. 22, ISSN 0250-7005, pages 2443 - 2446, XP008054734 [X] 1-5,9,11,19,21-22 * the whole document *-
SEARCH- KITAGUCHI KOHJI ET AL, "Immune deficiency enhances expression of recombinant human antibody in mice after nonviral in vivo gene transfer", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, SPANDIDOS PUBLICATIONS, GR, (20051001), vol. 16, no. 4, ISSN 1107-3756, pages 683 - 688, XP008118466 [Y] 24-26 * the whole document *-
SEARCH- "Non-Viral DNA and mRNA Gene Delivery to the CNS Pre-Operatively for Neuroprotection and Following Neurotrauma", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, (20040501), vol. 9, ISSN 1525-0016, page 258, XP004635047 [Y] 24-26 * the whole document *-
SEARCH- PRIMUS F ET AL, "SELF-REACTIVE ANTIBODY EXPRESSION BY HUMAN CARCINOMA CELLS ENGINEERED WITH MONOCLONAL ANTIBODY GENES", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (19930715), vol. 53, no. 14, ISSN 0008-5472, pages 3355 - 3361, XP002013764 [X] 1-5,9,11,19,21-23 * the whole document *-
SEARCH- CARRALOT J-P ET AL, "Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines", CMLS CELLULAR AND MOLECULAR LIFE SCIENCES, BIRKHAUSER VERLAG, HEIDELBERG, DE, (20040901), vol. 61, no. 18, doi:10.1007/S00018-004-4255-0, ISSN 1420-682X, pages 2418 - 2424, XP002355208 [Y] 24-26 * page 2418 - page 2419 *
SEARCH- PAUL R HESS ET AL, "Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20060601), vol. 55, no. 6, doi:10.1007/S00262-005-0064-Z, ISSN 1432-0851, pages 672 - 683, XP019333249 [Y] 20,24-26 * the whole document *
SEARCH- OHASHI ET AL, "Efficient protein selection based on ribosome display system with purified components", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, (20061130), vol. 352, no. 1, doi:10.1016/J.BBRC.2006.11.017, ISSN 0006-291X, pages 270 - 276, XP005725399 [X] 1-5,9,15-16,18,21 * page 271 *
SEARCH- BANDBON BALENGA ET AL, "Bicistronic expression plasmid encoding allergen and anti-IgE single chain variable fragment antibody as a novel DNA vaccine for allergy therapy and prevention", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, (20060101), vol. 67, no. 1, doi:10.1016/J.MEHY.2005.12.044, ISSN 0306-9877, pages 71 - 74, XP005397016 [Y] 24-26 * the whole document *
SEARCH[ ] - KOLB ET AL, "A virus-neutralising antibody is not cytotoxic in vitro", MOLECULAR IMMUNOLOGY, PERGAMON, GB, (20060201), vol. 43, no. 6, doi:10.1016/J.MOLIMM.2005.04.008, ISSN 0161-5890, pages 677 - 689, XP005211235 [ ] * page 681 *
SEARCH- HU ET AL, "Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in Pichia pastoris", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA, (20060501), vol. 47, no. 1, doi:10.1016/J.PEP.2005.11.014, ISSN 1046-5928, pages 249 - 257, XP005392638 [X] 1-5,7-10,15-16,18,21 * page 252 *
SEARCH- IVANOVSKA ET AL, "Immunization with a DNA chimeric molecule encoding a hemagglutinin peptide and a scFv CD21-specific antibody fragment induces long-lasting IgM and CTL responses to influenza virus", VACCINE, ELSEVIER LTD, GB, (20060310), vol. 24, no. 11, doi:10.1016/J.VACCINE.2005.10.029, ISSN 0264-410X, pages 1830 - 1837, XP005294681 [Y] 24-26 * the whole document *
SEARCH- BAKKER J M ET AL, "Therapeutic Antibody Gene Transfer: An Active Approach to Passive Immunity", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, (20040901), vol. 10, no. 3, doi:10.1016/J.YMTHE.2004.06.865, ISSN 1525-0016, pages 411 - 416, XP004660582 [Y] 24-26 * page 413 - page 414 *
SEARCH- ZEYTIN H E ET AL, "CONSTRUCTION AND CHARACTERIZATION OF DNA VACCINES ENCODING THE SINGLE-CHAIN VARIABLE FRAGMENT OF THE ANTI-IDIOTYPE ANTIBODY 1A7 MIMICKING THE TUMOR-ASSOCIATED ANTIGEN DISIALOGANGLIOSIDE GD2", CANCER GENE THERAPY, APPLETON & LANGE, GB, (20001101), vol. 7, no. 11, doi:10.1038/SJ.CGT.7700240, ISSN 0929-1903, pages 1426 - 1436, XP001145646 [Y] 24-26 * the whole document *
SEARCH- CARSTEN FINGER ET AL, "Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells", CANCER GENE THERAPY, (20050101), doi:10.1038/sj.cgt.7700805, ISSN 0929-1903, XP055039486 [X] 1-5,9,11,19,21-22 * the whole document *
SEARCH- WILLEMSEN R A ET AL, "A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes.", GENE THERAPY NOV 2001, (200111), vol. 8, no. 21, ISSN 0969-7128, pages 1601 - 1608, XP055028813 [X] 1-5,9,11,19,21-23 * the whole document *
SEARCH[ ] - PROBST J ET AL, "Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent", GENE THERAPY, NATURE PUBLISHING GROUP, GB, vol. 14, doi:10.1038/SJ.GT.3302964, ISSN 0969-7128, (20070503), pages 1175 - 1180, (20070503), XP002679377 [ ] * the whole document *
SEARCH- MAYFIELD STEPHEN P ET AL, "Expression and assembly of a fully active antibody in algae", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, (20030121), vol. 100, no. 2, doi:10.1073/PNAS.0237108100, ISSN 0027-8424, pages 438 - 442, XP002440629 [X] 1-5,9,15-16,18,21 * page 239 - page 240 *
SEARCH[ ] - KARIKO K ET AL, "mRNA Is an Endogenous Ligand for Toll-like Receptor 3", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 279, no. 13, doi:10.1074/JBC.M310175200, ISSN 0021-9258, (20040326), pages 12542 - 12550, (20040116), XP002598534 [ ] * the whole document *
SEARCH- ISAO FUKUDA ET AL, "In vitro evolution of single-chain antibodies using mRNA display", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, GB, vol. 34, no. 19, doi:10.1093/NAR/GKL618, ISSN 1362-4962, (20061101), pages E127 - 1, (20060929), XP002639193 [X] 1-5,9,15-16,18,21 * page second * [I] 6,12-13,17 [Y] 20
SEARCH[ ] - LESAFFRE BRIGITTE ET AL, "Direct non-cell autonomous Pax6 activity regulates eye development in the zebrafish", NEURAL DEVELOPMENT, BIOMED CENTRAL LTD, LO, (20070117), vol. 2, no. 1, doi:10.1186/1749-8104-2-2, ISSN 1749-8104, page 2, XP021026216 [ ] * page 11 *
SEARCH- PASCOLO S, "Vaccination with messenger RNA", METHODS IN MOLECULAR MEDICINE,, (20060101), ISSN 1543-1894, pages 23 - 40, XP009117840 [Y] 24-26 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents